AI assistant
NEOGENOMICS INC — Director's Dealing 2025
May 8, 2025
32227_dirs_2025-05-08_09ca20d0-2b74-4ca0-a6e3-0c1d5922fb07.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2025-05-06
Reporting Person: Zook Anthony P. (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-06 | Common Stock | P | 18900 | $7.8793 | Acquired | 18900 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 11336 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $14.82 | 2033-08-10 | Common Stock (8353) | 8353 | Direct |
| Stock Option (Right to Buy) | $13.71 | 2034-06-01 | Common Stock (8672) | 8672 | Direct |
| Restricted Stock Unit | $0 | Common Stock (12254) | 12254 | Direct | |
| Stock Option (Right to Buy) | $10.44 | 2035-04-01 | Common Stock (729927) | 729927 | Direct |
| Restricted Stock Unit | $0 | Common Stock (421496) | 421496 | Direct |
Footnotes
F1: Once vested, the shares of common stock are not subject to expiration.
F2: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.
F3: On April 1, 2025, Mr. Zook was granted 729,927 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F4: On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.